

Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

Information for the public
Published: 16 March 2022

www.nice.org.uk

Dostarlimab (Jemperli) is available through the [Cancer Drugs Fund](#). It is a possible treatment for advanced or recurrent endometrial cancer in adults if:

- their tumours have high microsatellite instability or mismatch repair deficiency and
- they have had platinum-based chemotherapy.

More evidence on dostarlimab is being collected. After this NICE will decide whether or not to recommend it for use on the NHS and update the guidance. It will be available through the Cancer Drugs Fund until then.

If you are not eligible for dostarlimab but are already having it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS website](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Peaches Womb Cancer Trust](#), admin@peachestrust.org
- [Go Girls](#), 07340 528 902
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-4490-3